Disclaimer: Early release articles are not considered as final versions. Any changes will be reflected in the online version in the month the article is officially released.
Volume 31, Supplement—October 2025
SUPPLEMENT ISSUE
Supplement
Nonspecific Symptoms Attributable to Lyme Disease in High-Incidence Areas, United States, 2017–2021
Courtney C. Nawrocki, Mark J. Delorey, Austin R. Earley, Sarah A. Hook, Kiersten J. Kugeler, Grace E. Marx, Paul S. Mead, and Alison F. Hinckley
Table 2
Risk for nonspecific symptom codes among case-patients and control-patients in the prediagnosis and postdiagnosis years in study of nonspecific symptoms attributable to Lyme disease in high-incidence areas, United States, 2017–2021
| Measure | Any symptom | Pain | Fatigue | Cognitive difficulties |
|---|---|---|---|---|
| Risk ratio prediagnosis (95% CI) |
1.05 (1.03–1.07) |
1.03 (1.01–1.05) |
1.35 (1.29–1.41) |
0.91 (0.81–1.01) |
| Risk ratio postdiagnosis (95% CI) |
1.12 (1.11–1.14) |
1.10 (1.08–1.12) |
1.67 (1.61–1.72) |
1.18 (1.08–1.28) |
| Ratio of relative risks (95% CI) |
1.07 (1.05–1.10) |
1.07 (1.04–1.10) |
1.24 (1.17–1.30) |
1.30 (1.13–1.49) |
| Attributable risk postdiagnosis, % | 10.9 | 8.7 | 40.2 | 16.1 |
Page created: August 27, 2025
Page updated: November 14, 2025
Page reviewed: November 14, 2025
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.